鸟苷酸环化酶-C作为胃肠道疾病治疗靶点
功能性胃肠病(FGIDs)和炎症性肠病(IBD)是常见的胃肠道疾病,消耗大量医疗资源。近期研究显示,胃肠道黏膜的膜结合鸟苷酸环化酶-C(GC-C)受体可能成为治疗FGIDs和IBD的新靶点。本文综述GC-C在健康与疾病中的功能认识进展,以及将这些原理转化为FGIDs和IBD新治疗策略的方法。
要点
- GC-C受体被尿鸟苷素和鸟苷素激活后,以pH依赖方式产生环磷酸鸟苷(cGMP)。
- GC-C信号轴调节液体和电解质稳态、肠道屏障、抗炎活性和上皮再生。
- GC-C受体在慢性特发性便秘和便秘型肠易激综合征中显示治疗潜力。
核心结论
- GC-C旁分泌信号轴在治疗FGIDs和IBD方面具有治疗潜力。
研究设计与样本
- 综述,聚焦GC-C功能在健康与疾病中的认识进展及转化策略。
主要发现
- GC-C受体激活由尿鸟苷素和鸟苷素以pH依赖方式介导,产生cGMP。
- GC-C信号调节液体和电解质稳态、肠道屏障维持、抗炎活性和上皮再生。
- GC-C受体在慢性特发性便秘和便秘型肠易激综合征中显示治疗潜力。
关键数值与推荐
- GC-C受体激活由内源性旁分泌激素尿鸟苷素和鸟苷素触发,下游效应物为环磷酸鸟苷(cGMP),呈pH依赖方式。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Functional gastrointestinal disorders (FGIDs) and IBDs are two of the most prevalent disorders of the GI tract and consume a significant proportion of healthcare resources. Recent studies have shown that membrane-bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic targets in the treatment of FGIDs and IBDs. GC-C receptor activation by its endogenous paracrine hormones uroguanylin and guanylin, and the resulting intracellular production of its downstream effector cyclic GMP, occurs in a pH-dependent manner and modulates key physiological functions. These include fluid and electrolyte homeostasis, maintenance of the intestinal barrier, anti-inflammatory activity and regulation of epithelial regeneration. Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of these receptors in treating GI disorders, including chronic idiopathic constipation and irritable bowel syndrome-constipation. This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.
引用
- Waldman SA, Camilleri M. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut. 2018. PMID: 29563144. doi:10.1136/gutjnl-2018-316029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。